IMMU — Mendus AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK346.22m
- SEK304.26m
Brief: Mendus Receives ATMP Certificate From European Medicines Agency
Brief: Mendus Announces Share, Rights Issues Totaling About SEK 317 Mln
Brief: Mendus And Northx Biologics To Enter Into Strategic Cell Therapy Manufacturing Alliance
Brief: Mendus Secures Shareholder Loan Of SEK 15 Mln
Brief: Mendus Q1 Operating Loss Widens To SEK 29.6 Mln
Brief: Mendus Announces Request For Conversion Of Convertible Bonds By Negma Group
Brief: Mendus Announces Request For Conversion Of Convertible Bonds By Negma Group
Brief: Mendus Announces Request For Conversion Of Convertible Bonds By Negma Group
Brief: Mendus Says Request For Conversion Of Convertible Bonds By Negma Group
Brief: Mendus Announces Request For Conversion Of Convertible Bonds By Negma Group
Brief: Mendus To Present Positive Interim Data From ALISON Trial In Ovarian Cancer
Brief: Mendus Announces Request For Conversion Of Convertible Bonds By Negma Group
Brief: Mendus Secures Second Loan From Van Herk Investments
Brief: Mendus Says Announces Request For Conversion Of Convertible Bonds By Negma Group
Brief: Mendus AB Q4 Operating Loss Widens To SEK 41.6 Mln
Brief: Mendus Gets Request For Conversion Of Convertible Bonds By Negma
Brief: Mendus Announces Request Of First Tranche Of Convertible Loan From Negma Group
Brief: Mendus AB (Publ) Mendus Presents Positive Survival Data From Advance Ii Trial Evaluating Dcp-001 As A Maintenance Therapy In Aml
Brief: Immunicum Q3 Operating Loss SEK 37.4 Million